SynthesisBMC neurology2026
Safety and efficacy of calcitonin gene-related peptide antagonists for cluster headache: a systematic review and meta-analysis.
Synthesis in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Calcitonin Gene-Related Peptide (CGRP): Biology, Signaling, Pathophysiological Roles, and Therapeutic Applications.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCalcitonin gene-related peptide is an emerging therapeutic target in cluster headache, yet evidence on the preventive efficacy and safety of calcitonin gene-related peptide antagonists remains limited. This systematic review and meta-analysis assessed the efficacy and safety of calcitonin gene-related peptide antagonists in adults with Cluster headache.
methodsWe searched PubMed, Web of Science, Cochrane CENTRAL, ClinicalTrials.gov, and EBSCO for randomized controlled and single-arm trials involving episodic and chronic cluster headache. Safety outcomes evaluate the treatment-emergent adverse events, serious adverse events, and treatment discontinuations, while efficacy outcomes included the change from baseline in the mean number of weekly attacks, the proportion of participants achieving a ≥ 50% or ≥ 30% reduction in weekly attack frequency, and those reporting a "much improved" or "very much improved" status on the Patient Global Impression of Change scale.
resultsFour randomized controlled trials and two single-arm trials were included. Calcitonin gene-related peptide antagonists reduced weekly attacks by a mean of -7.23 (95% CI: - 9.86 to - 4.60). ≥ 50% responder rate was 46% (95% CI: 26%-67%) and ≥ 30% responder rate was 59% (95% CI: 45%-73%). Efficacy effects were larger in episodic than in chronic Cluster headache. The pooled proportion of patients experiencing at least one TEAE was 60% (95% CI: 35%-82%). SAEs (4%, 95% CI: 1%-9%) and discontinuations (3%, 95% CI: 1%-7%) were uncommon.
conclusionCalcitonin gene-related peptide antagonists provide preventive benefit with acceptable safety in cluster headache. These findings should be interpreted as supportive but less definitive. Larger, long-term, placebo-controlled randomized trials are needed to confirm efficacy and guide clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.